Clinical Trial Update: Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating continuous versus intermittent dosing of pomalidomide in relapsed/refractory multiple myeloma; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalyst (pomalidomide)

Snippet

Sponsor: Yale University | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-08-11